NAYA Therapeutics has selected Atley Solutions for Astatine-related pharmaceutical development and manufacturing, as a partner and supplier to accelerate the development, pre-clinical and clinical translation, and commercialisation of NAYA's ²¹¹At radiopharmaceuticals. This will involve making use of Atley's radiopharmaceutical manufacturing platform (Atley C100), development services and planned network of clinical manufacturing and development partners.

"We're thrilled to partner with Atley Solutions, a leader in the advancement of Astatine-211 as a preferred radionuclide. This partnership will enable us to use Atley's scalable and automated Atley C100 manufacturing module, which allows for the purification, conjugation and preparation of therapeutic doses in close proximity to outpatient treatments centres – a breakthrough in unlocking a scalable ²¹¹At supply chain. In addition, we plan to leverage and expand on Atley's planned decentralised manufacturing and clinical development network, allowing us to enroll patients in clinical trials globally, starting with NY-703, our GPC3-targeting ²¹¹At targeted alpha therapy for the treatment of hepatocellular carcinoma," " commented Dr Daniel Teper, CEO, NAYA.

NY-703 is a GPC3-targeting astatine-211 (²¹¹At) targeted alpha therapy for the treatment of residual and metastatic HepatoCellular Carcinoma (HCC), aiming to achieve initial clinical data in 2026. It consists of a GPC3-antibody fragment F(ab')2 conjugated to an Astatine-211 isotope through an optimised proprietary linker. Hepatocellular Carcinoma is a rapidly-growing cancer with an estimated one million new patients every year and a lack of safe and effective therapeutic options.

"Astatine-211's short half-life, clean decay, chelatorless chemistry and ability to be produced using naturally-abundant Bismuth-209 address key safety and supply limitations of other alpha and beta emitters and make it a highly-promising radionuclide for multiple therapeutic applications. We're delighted to partner with NAYA, one of the pioneering biotech companies advancing Astatine-211 therapeutics to clinical and commercial use, and deliver the transformative potential of these therapies to patients," said Milton Lönnroth, CEO, Atley Solutions.